Expanding Accessibility and Convenience in Drug Delivery Systems

The pharmaceutical landscape is currently undergoing a transformative shift towards prioritizing oral dosage forms, especially in the context of treating rare diseases and chronic conditions. Amid the COVID-19 pandemic's influence on drug delivery preferences, oral solid dosage pharmaceuticals have maintained a significant market presence, accounting for a substantial 23.8% share of the global pharmaceutical drug delivery market in 2021. 

Within the realm of rare diseases, this report highlights significant milestones, including the approval of an oral therapy in 2020 for Hereditary Angioedema, marking a groundbreaking advancement in the treatment of rare disorders. Additionally, the report discusses PharmaTher's orphan designation approval for the investigation of ketamine oral formulation for Rett syndrome. Furthermore, notable strides have been made in monoclonal antibody technology, exemplified by Rani Therapeutics' RaniPill™ capsule. This innovative approach delivers medication to the intestinal wall, offering a painless injection experience due to the absence of sharp pain receptors, the report also examines the strategic significance of extending patent life through innovative dosage forms. A compelling case study is Semaglutide, with its patent extension for the oral formulation until 2032 and as a film-coated tablet until 2042, illustrating the value of innovative drug delivery methods in maintaining market competitiveness.